Hard to see what is really going to move the SP (up) with the half year numbers. I guess with dose sales at the upper end of the forecast (5.6%) we should expect EBITDA should be as well - $32m? I can't see SRX pulling a rabbit out of the hat here - even xrates are going against us. Maybe some clarification on dates re announcements on trials but overall I think I will be happy if the SP stays where it is. Anyway one more sleep to go.
Add to My Watchlist
What is My Watchlist?